Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

A 21-year-old shares progress 1.5 months after starting finasteride (0.5 mg every other day) with no side effects, using minoxidil for beard growth, rosemary oil, and weekly microneedling. They report healthier hair texture and positive feedback from family.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

The user has been using 1mg Finasteride and 5% topical Minoxidil for 9 months with little improvement and has recently added microneedling, showing slight progress. The new protocol includes switching to 5mg oral Minoxidil, continuing microneedling, and adding Anagenil Complex, while seeking advice on whether to stop topical Minoxidil and the effectiveness of Anagenil Complex.

User discusses Alfatradiol (17a-Estradiol) as a potential hair loss treatment with mixed results. Concerns include low dosage, receptor theory, and possible increased aromatase activity on scalp.

The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

A user is taking 1mg oral finasteride daily and using a Korean caffeine scalp shampoo for hair loss, reporting positive growth after one month without side effects. Another user suggests waiting six months for more noticeable results.

The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.

A 22-year-old male started taking finasteride a month ago and is seeing some progress in hair loss treatment. He is concerned about high estradiol levels but plans to continue the medication and consult an endocrinologist.

Creating a liposomal gel with Pyrilutamide for hair loss to reduce systemic effects, similar to Xyon's gel. The discussion includes concerns about ingredient sourcing and the benefits of targeted topical treatments.

The user has seen significant hair regrowth after one year using 1mg oral finasteride and 5% topical minoxidil, considering a hair transplant if progress stalls. They experienced an initial shedding phase and temporary erectile dysfunction, but no other side effects.

The post and conversation are about a user's progress with microneedling and minoxidil for hair loss. The user is happy with the progress and plans to continue with the treatment, without using finasteride.

The user stopped using topical minoxidil and finasteride after 2.5 months and switched to oral finasteride, 1mg daily, and did microneedling 1.5mm seven times. They experienced occasional sleep issues and watery semen as side effects, which stopped after discontinuing the topical treatment.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Microneedling pens for hair loss, with users discussing brands like Korabeauticals v2, Dr Pen, and Derminator 2. Some users report using oral minoxidil but have not seen regrowth yet.

A new trial for Verteporfin to treat hair loss will start in LA, led by Dr. Behnam. Users are hopeful it could be a breakthrough treatment.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

A 30-year-old man experienced significant hair regrowth and improved libido after using finasteride and dutasteride for androgenetic alopecia, with no adverse effects. He plans to reduce dutasteride dosage when trying to conceive and has been using topical minoxidil since 2015.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

The user has been on finasteride for a year but continues to experience hair loss and side effects like low libido and sensitive nipples. They are considering stopping the treatment and possibly buzzing their head due to the lack of improvement and ongoing issues.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

A user shared impressive hair growth results after 77 days using oral finasteride, topical minoxidil, and weekly microneedling. They reported thicker, darker hair and minimal shedding, with treatment costs around 30 euros per month.

A 29-year-old woman with genetic hair loss started using 0.5 dutasteride a week ago and has noticed increased shedding, no sexual side effects, and less oily skin. She plans to provide updates and is not concerned about potential birth defects as she doesn't plan to have more children.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The user has been using Essengen 6+ (a mix of low-dose topical finasteride and minoxidil) for three months, seeing positive results, especially on the crown area. They also use Nizoral for dandruff and dermaroll weekly.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

The conversation is about the release date of pyrilutamide for hair loss treatment. No specific release date is provided.